Changes in Serum Adiponectin Concentrations Correlate With Changes in BMI, Waist Circumference, and Estimated Visceral Fat Area in Middle-Aged General Population

Diabetes Care, Oct 2009

Yukiyoshi Okauchi, Ken Kishida, Tohru Funahashi, Midori Noguchi, Tomoko Ogawa, Miwa Ryo, Kohei Okita, Hiromi Iwahashi, Akihisa Imagawa, Tadashi Nakamura, et al.

A PDF file should load here. If you do not see its contents the file may be temporarily unavailable at the journal website or you do not have a PDF plug-in installed and enabled in your browser.

Alternatively, you can download the file locally and open with any standalone PDF reader:

https://care.diabetesjournals.org/content/32/10/e122.full.pdf

Changes in Serum Adiponectin Concentrations Correlate With Changes in BMI, Waist Circumference, and Estimated Visceral Fat Area in Middle-Aged General Population

0 Kawasaki Hos- pital, Kobe, Hyogo, Japan 1 Amagasaki City Office, General Affairs Bureau, Personal Department, Payroll Section, Employee Health Promotion Sec- tion , Amagasaki, Hyogo, Japan 2 Department of Metabolic Medicine, Graduate School of Medicine, Osaka University , Suita, Osaka, Japan ; the 3 Sumitomo Hospital , Osaka, Japan Acknowledgments No potential conflicts of interest relevant to this article were reported. - A pocytokine in the human adipose diponectin was identified as an aditissue cDNA library. It has antiatherosclerotic and antidiabetic properties in experimental studies, and its blood levels are low in obesity, diabetes, cardiovascular diseases, and metabolic syndrome. Several studies have reported that weight reduction in massively obese subjects is associated with a rise in serum adiponectin (APN) concentration (13). However, the relationship between changes in APN and BMI, waist circumference (WC), and visceral fat accumulation (VFA) in general population has not been reported. The present study investigated 1-year change in APN (APN) in relation to changes in BMI (BMI), WC (WC), and estimated visceral fat area (eVFA) in middle-aged general population. The study subjects were 2,024 middle-aged Japanese (1,619 men [45.7 10.4 years] and 405 women [45.6 9.3 years], mean SD) who were employees of Amagasaki city office and had undergone annual health checkup in both 2004 and 2005 and were not taking any medications for diabetes, hypertension, or dyslipidemia. The study was approved by the human ethics committee of Osaka University, and a signed informed consent was obtained from each participant. Height, weight, and WC were measured in standing position. BMI was calculated as weight in kilograms divided by the square of height in meters. WC at umbilical level was measured with a nonstretchable tape in late expiration while standing (in cm). VFA was estimated noninvasively by bioelectrical impedance analysis (BIA) (4). Briefly, the voltage recorded at the flank to the flow of current between the umbilicus and the back correlates significantly with VFA and is not influenced by subcutaneous fat. We reported previously that VFA estimated by BIA correlates significantly with that determined by computed tomography (4). APN was measured using latex particle enhanced turbidimetric assay (5). APN correlated negatively with BMI, both in men (r 0.256, P 0.0001) and women (r 0.223, P 0.0001) and with WC in men only (r 0.191, P 0.0001), but no correlation was found in women (P 0.097), and APN correlated negatively with eVFA in both men (r 0.189, P 0.0001) and women (r 0.121, P 0.015). APN is likely influenced by genetic and environmental factors. It has been reported that APN is associated with single nucleotide polymorphisms in adiponectin gene. The present study demonstrated that changes in body fat, i.e., reduction in BMI, WC, and eVFA, correlated with a rise in APN in middle-aged general population, which to our knowledge is the first such report. We used BIA to evaluate VFA in the present study, and further research on both visceral and subcutaneous fat areas measured by computed tomography scan is needed to clarify the effects of visceral and subcutaneous adiposity on APN. YUKIYOSHI OKAUCHI, MD1 KEN KISHIDA, MD1 TOHRU FUNAHASHI, MD1 MIDORI NOGUCHI, RN2 TOMOKO OGAWA, RN2 MIWA RYO, MD1 KOHEI OKITA, MD1 HIROMI IWAHASHI, MD1 AKIHISA IMAGAWA, MD1 TADASHI NAKAMURA, MD3 YUJI MATSUZAWA, MD4 IICHIRO SHIMOMURA, MD1 References 1. Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, Iwahashi H, Kuriyama H, Ouchi N, Maeda K, Nishida M, Kihara S, Sakai N, Nakajima T, Hasegawa K, Muraguchi M, Ohmoto Y, Nakamura T, Yamashita S, Hanafusa T, Matsuzawa Y. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000;20:1595 1599 2. Yang WS, Lee WJ, Funahashi T, Tanaka S, Matsuzawa Y, Chao CL, Chen CL, Tai TY, Chuang LM. Weight reduction increases plasma levels of an adipose-derived antiinflammatory protein, adiponectin. J Clin Endocrinol Metab 2001;86:38153819 3. Ng TW, Watts GF, Barrett PH, Rye KA, Chan DC. Effect of weight loss on LDL and HDL kinetics in the metabolic syndrome: associations with changes in plasma retinol-binding protein-4 and adiponectin levels. Diabetes Care 2007;30: 29452950 4. Ryo M, Maeda K, Onda T, Katashima M, Okumiya A, Nishida M, Yamaguchi T, Funahashi T, Matsuzawa Y, Nakamura T, Shimomura I. A new simple method for the measurement of visceral fat accumulation by bioelectrical impedance. Diabetes Care 2005;28:451 453 5. Nishimura A, Sawai T. Determination of adiponectin in serum using a latex particle-enhanced turbidimetric immunoassay with an automated analyzer. Clin Chim Acta 2006;371:163168


This is a preview of a remote PDF: https://care.diabetesjournals.org/content/32/10/e122.full.pdf

Yukiyoshi Okauchi, Ken Kishida, Tohru Funahashi, Midori Noguchi, Tomoko Ogawa, Miwa Ryo, Kohei Okita, Hiromi Iwahashi, Akihisa Imagawa, Tadashi Nakamura, Yuji Matsuzawa, Iichiro Shimomura. Changes in Serum Adiponectin Concentrations Correlate With Changes in BMI, Waist Circumference, and Estimated Visceral Fat Area in Middle-Aged General Population, Diabetes Care, 2009, e122-e122, DOI: 10.2337/dc09-1130